The prognostic factors in acute myeloid leukaemia with double-mutated CCAAT/enhancer-binding protein alpha (CEBPAdm).
CEBPA mutations
CSF3R mutations
acute myeloid leukaemia
induction
prognosis
Journal
British journal of haematology
ISSN: 1365-2141
Titre abrégé: Br J Haematol
Pays: England
ID NLM: 0372544
Informations de publication
Date de publication:
05 2022
05 2022
Historique:
revised:
13
02
2022
received:
04
01
2022
accepted:
15
02
2022
pubmed:
12
3
2022
medline:
11
5
2022
entrez:
11
3
2022
Statut:
ppublish
Résumé
The prognostic factors to stratify acute myeloid leukaemia (AML) with double-mutated CCAAT/enhancer-binding protein alpha (CEBPAdm) into different risk groups remains to be determined. In this retrospective study, we evaluated 171 consecutive patients with newly diagnosed AML with CEBPAdm by a Cox proportional hazards regression model. In univariate analyses, colony stimulating factor 3 receptor (CSF3R) and Wilms tumour 1 (WT1) mutations were associated with poor relapse-free survival (RFS). The induction regimens including homoharringtonine (omacetaxine mepesuccinate) or intermediate-dose cytarabine was associated with favourable RFS and overall survival (OS). The induction regimen including both homoharringtonine and intermediate-dose cytarabine was associated with the most favourable RFS (3-year RFS 84.7%) and OS (3-year OS 92.8%) compared to the conventional cytarabine and daunorubicin regimen (3-year RFS 27.7%, hazard ratio [HR] 0.126, 95% confidence interval [CI] 0.051-0.313, Wald p < 0.001; and 3-year OS 56.4%, HR 0.179, 95% CI 0.055-0.586, Wald p = 0.005). In multivariate analyses, the induction regimen including intermediate-dose cytarabine (HR 0.364, 95% CI 0.205-0.646, Wald p < 0.001) and CSF3R mutations (HR 2.667, 95% CI 1.276-5.572, Wald p = 0.009) were independently associated with RFS. Taken together, we found that induction regimen and CSF3R mutations were independent prognostic factors for AML with CEBPAdm.
Substances chimiques
CCAAT-Enhancer-Binding Protein-alpha
0
CCAAT-Enhancer-Binding Proteins
0
CSF3R protein, human
0
Receptors, Colony-Stimulating Factor
0
Cytarabine
04079A1RDZ
Homoharringtonine
6FG8041S5B
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
442-451Informations de copyright
© 2022 British Society for Haematology and John Wiley & Sons Ltd.
Références
Dohner H, Weisdorf DJ, Bloomfield CD. Acute myeloid leukemia. N Engl J Med. 2015;373:1136-52.
Ferrara F, Schiffer CA. Acute myeloid leukaemia in adults. Lancet. 2013;381:484-95.
Wei H, Wang Y, Zhou C, Lin D, Liu B, Liu K, et al. Distinct genetic alteration profiles of acute myeloid leukemia between Caucasian and eastern Asian population. J Hematol Oncol 2018;11:18.
Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127:2391-405.
National Comprehensive Cancer Network NCCN Clinical Practice Guidelines in Oncology: Acute Myeloid Leukemia Version 3.2020. Available from: http://nccndd.qitian-med.tech/nccn-his/%E6%80%A5%E6%80%A7%E9%AB%93%E6%80%A7%E7%99%BD%E8%A1%80%E7%97%85/%E6%80%A5%E6%80%A7%E9%AB%93%E6%80%A7%E7%99%BD%E8%A1%80%E7%97%852020.3%E7%89%88.pdf
Döhner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, Büchner T, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood 2017;129:424-47.
Leukemia & Lymphoma Group, Chinese Society of Hematology, Chinese Medical Association. Chinese guidelines for diagnosis and treatment of adult acute myeloid leukemia (not APL) (2017). Zhonghua Xue Ye Xue Za Zhi 2017;38:177-82.
Green CL, Koo KK, Hills RK, Burnett AK, Linch DC, Gale RE. Prognostic significance of CEBPA mutations in a large cohort of younger adult patients with acute myeloid leukemia: impact of double CEBPA mutations and the interaction with FLT3 and NPM1 mutations. J Clin Oncol. 2010;28:2739-47.
Taskesen E, Bullinger L, Corbacioglu A, Sanders MA, Erpelinck CAJ, Wouters BJ, et al. Prognostic impact, concurrent genetic mutations, and gene expression features of AML with CEBPA mutations in a cohort of 1182 cytogenetically normal AML patients: further evidence for CEBPA double mutant AML as a distinctive disease entity. Blood 2011;117:2469-75.
Schlenk RF, Taskesen E, van Norden Y, Krauter J, Ganser A, Bullinger L, et al. The value of allogeneic and autologous hematopoietic stem cell transplantation in prognostically favorable acute myeloid leukemia with double mutant CEBPA. Blood 2013;122:1576-82.
Wouters BJ, Löwenberg B, Erpelinck-Verschueren CA, van Putten WL, Valk PJ, Delwel R. Double CEBPA mutations, but not single CEBPA mutations, define a subgroup of acute myeloid leukemia with a distinctive gene expression profile that is uniquely associated with a favorable outcome. Blood. 2009;113:3088-91.
Theis F, Corbacioglu A, Gaidzik VI, Paschka P, Weber D, Bullinger L, et al. Clinical impact of GATA2 mutations in acute myeloid leukemia patients harboring CEBPA mutations: a study of the AML study group. Leukemia 2016;30:2248-50.
Li Y, Zhang J, Wei H, Wang Y, Liu B, Lin D, et al. Clinical, cytogenetic characteristics and survival of acute Leukemia in a National Research Center Database, 10-year real-world data review. Blood. 2021;138(Suppl 1):3062.
Wei H, Wang Y, Gale RP, Lin D, Zhou C, Liu B, et al. Randomized trial of intermediate-dose cytarabine in induction and consolidation therapy in adults with acute myeloid Leukemia. Clin Cancer Res 2020;26:3154-61.
Wei H, Zhou C, Lin D, Liu B, Li Y, Zhao X, et al. Benefit of intermediate-dose cytarabine containing induction in molecular subgroups of acute myeloid leukemia. Haematologica 2020;106:1491-5.
Wang J, Lu R, Wu Y, Jia J, Gong L, Liu X, et al. Detection of measurable residual disease may better predict outcomes than mutations based on next-generation sequencing in acute myeloid leukaemia with biallelic mutations of CEBPA. Br J Haematol 2020;190:533-44.
Jin J, Wang JX, Chen FF, Wu DP, Hu J, Zhou JF, et al. Homoharringtonine-based induction regimens for patients with de-novo acute myeloid leukaemia: a multicentre, open-label, randomised, controlled phase 3 trial. Lancet Oncol 2013;14:599-608.
Su L, Tan Y, Lin H, Liu X, Yu L, Yang Y, et al. Mutational spectrum of acute myeloid leukemia patients with double mutations based on next-generation sequencing and its prognostic significance. Oncotarget 2018;9:24970-9.
Su L, Gao S, Tan Y, Lin H, Liu X, Liu S, et al. CSF3R mutations were associated with an unfavorable prognosis in patients with acute myeloid leukemia with CEBPA double mutations. Ann Hematol 2019;98:1641-6.
Tien FM, Hou HA, Tang JL, Kuo YY, Chen CY, Tsai CH, et al. Concomitant WT1 mutations predict poor prognosis in acute myeloid leukemia patients with double mutant. Haematologica 2018;103:e510-3.
Greif PA, Dufour A, Konstandin NP, Ksienzyk B, Zellmeier E, Tizazu B, et al. GATA2 zinc finger 1 mutations associated with biallelic CEBPA mutations define a unique genetic entity of acute myeloid leukemia. Blood 2012;120:395-403.